Evidence map›Paper›PMID 39702399›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2025

GD2-targeted theranostics of neuroblastoma with [

Lingling Zheng, Cuicui Li, Xu Yang, Jun Liu, Guanyun Wang, Ziang Zhou, Xianyu Zhu, Jianhua Gong, Jigang Yang

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. [European journal of nuclear medicine and molecular imaging · 2025
    Trial
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Lingling ZhengDepartment of Nuclear Medicine, Beijing Friendship Hospital Affiliated to Capital Medical University, 95 Yong'an Rd., Xicheng Dist, Beijing, 100050, China.
Cuicui LiDepartment of Nuclear Medicine, Beijing Friendship Hospital Affiliated to Capital Medical University, 95 Yong'an Rd., Xicheng Dist, Beijing, 100050, China.
Xu YangDepartment of Nuclear Medicine, Beijing Friendship Hospital Affiliated to Capital Medical University, 95 Yong'an Rd., Xicheng Dist, Beijing, 100050, China.
Jun LiuDepartment of Nuclear Medicine, Beijing Friendship Hospital Affiliated to Capital Medical University, 95 Yong'an Rd., Xicheng Dist, Beijing, 100050, China.
Guanyun WangDepartment of Nuclear Medicine, Beijing Friendship Hospital Affiliated to Capital Medical University, 95 Yong'an Rd., Xicheng Dist, Beijing, 100050, China.
Ziang ZhouDepartment of Nuclear Medicine, Beijing Friendship Hospital Affiliated to Capital Medical University, 95 Yong'an Rd., Xicheng Dist, Beijing, 100050, China.
Xianyu ZhuDepartment of Nuclear Medicine, Beijing Friendship Hospital Affiliated to Capital Medical University, 95 Yong'an Rd., Xicheng Dist, Beijing, 100050, China. zhuxy0721@126.com.
Jianhua GongDepartment of Oncology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Courtyard No. 2, Nanwei Rd., Xicheng Dist, Beijing, 100050, China. ann_gong@imb.pumc.edu.cn.
Jigang YangDepartment of Nuclear Medicine, Beijing Friendship Hospital Affiliated to Capital Medical University, 95 Yong'an Rd., Xicheng Dist, Beijing, 100050, China. yangjigang@ccmu.edu.cn.ORCID 0000-0002-0538-7676

Funding

Beijing Friendship Hospital Seed Project of Capital Medical University YYZZ202337Beijing Friendship Hospital Seed Project of Capital Medical University YYZZ202352National Natural Science Foundation of China 82102088National Natural Science Foundation of China 82272034National Natural Science Foundation of China 82302235Natural Science Foundation of Beijing Municipality 7232031Natural Science Foundation of Beijing Municipality 7234359Noncommunicable Chronic Diseases-National Science and Technology Major Project 2023ZD0512000
6 · The paper itself

Abstract

purposeNeuroblastoma (NB) is a malignant embryonic tumour with poor prognosis and high mortality rate. The antigen gisialoganglioside (GD2), which is highly expressed on the surface of NB cells, is an effective target for therapy. This study aims to evaluate the GD2 expression with [

methodsThe in vitro validation of the binding ability of anti-GD2 humanised monoclonal antibody (hu3F8) to GD2 was achieved via flow cytometry, cell immunofluorescence, and cell uptake test. Hu3F8 were conjugated with p-SCN-Bn-NOTA (NOTA) and p-SCN-Bn-DOTA (DOTA) for

resultsThe Institute for Medical Research-32 (IMR32) cell line exhibited a specific binding ability of hu3F8. PET imaging demonstrated a specific accumulation of [

conclusionThis study demonstrated that

Indexed as

Copper RadioisotopesLutetiumNeuroblastomaRadioisotopesTheranostic NanomedicineAnimalsCell Line, TumorFemaleGangliosidesHumansMicePositron-Emission TomographyRadioimmunotherapyCopper-64Copper Radioisotopesganglioside, GD2GangliosidesLutetiumLutetium-177RadioisotopesCu-64GD2ImmunoPETLu-177NeuroblastomaRadioimmunotherapy

Identifiers

PMID39702399

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.